Practical management of liver transplant recipients for hepatitis C.
Hepatitis C is one of the leading indications for liver transplantation. Recipients can expect at least a short-term survival equivalent to other indications for liver transplantation. However, the rates of cirrhosis and decompensation development is substantially faster than those rates seen in non-transplant setting. Advances in antiviral therapy are now associated with a sustained virological response of 20% with combination antiviral with interferon and ribavirin. Higher response rates are expected with utilizing pegylated interferon.
Saab
S
S
Division of Digestive Diseases, Department of Medicine, University of California, Los Angeles, USA. Ssaab@mednet.ucla.edu
Busuttil
R W
RW
D000998:Antiviral Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018450:Disease Progression; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000209:etiology / Q000517:prevention & control; D016031:Liver Transplantation / Q000009:adverse effects / Q000706:statistics & numerical data; D011092:Polyethylene Glycols / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012008:Recurrence; D012086:Reoperation; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a